Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share By
Griscelli Syndrome Type 2 Sine Albinism: Unraveling Differential Rab27a Effector Engagement Publisher Pubmed



Ohishi Y1 ; Ammann S2, 3 ; Ziaee V4, 5 ; Strege K3 ; Gro M2 ; Amos CV3 ; Shahrooei M6 ; Ashournia P7 ; Razaghian A7 ; Griffiths GM3 ; Ehl S2 ; Fukuda M1 ; Parvaneh N7, 8
Authors

Source: Frontiers in Immunology Published:2020


Abstract

Griscelli syndrome type 2 (GS-2) is an inborn error of immunity characterized by partial albinism and episodes of hemophagocytic lymphohistiocytosis (HLH). It is caused by RAB27A mutations that encode RAB27A, a member of the Rab GTPase family. RAB27A is expressed in many tissues and regulates vesicular transport and organelle dynamics. Occasionally, GS-2 patients with RAB27A mutation display normal pigmentation. The study of such variants provides the opportunity to map distinct binding sites for tissue-specific effectors on RAB27A. Here we present a new case of GS-2 without albinism (GS-2 sine albinism) caused by a novel missense mutation (Val143Ala) in the RAB27A and characterize its functional cellular consequences. Using pertinent animal cell lines, the Val143Ala mutation impairs both the RAB27A–SLP2-A interaction and RAB27A–MUNC13-4 interaction, but it does not affect the RAB27A–melanophilin (MLPH)/SLAC2-A interaction that is crucial for skin and hair pigmentation. We conclude that disruption of the RAB27A–MUNC13-4 interaction in cytotoxic lymphocytes leads to the HLH predisposition of the GS-2 patient with the Val143Ala mutation. Finally, we include a review of GS-2 sine albinism cases reported in the literature, summarizing their genetic and clinical characteristics. © Copyright © 2020 Ohishi, Ammann, Ziaee, Strege, Groß, Amos, Shahrooei, Ashournia, Razaghian, Griffiths, Ehl, Fukuda and Parvaneh.
Other Related Docs
5. Whole Exome Sequencing for Mutation Screening in Hemophagocytic Lymphohistiocytosis, Iranian Journal of Pediatric Hematology and Oncology (2020)